GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nutra Pharma Corp (OTCPK:NPHC) » Definitions » Beneish M-Score

Nutra Pharma (Nutra Pharma) Beneish M-Score : 0.00 (As of Jun. 06, 2024)


View and export this data going back to . Start your Free Trial

What is Nutra Pharma Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Nutra Pharma's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Nutra Pharma was 0.00. The lowest was 0.00. And the median was 0.00.


Nutra Pharma Beneish M-Score Historical Data

The historical data trend for Nutra Pharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nutra Pharma Beneish M-Score Chart

Nutra Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.36 -32.16 -10.75 -9.89 -1.45

Nutra Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.88 -1.45 - -4.70 -8.63

Competitive Comparison of Nutra Pharma's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Nutra Pharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nutra Pharma's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nutra Pharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Nutra Pharma's Beneish M-Score falls into.



Nutra Pharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Nutra Pharma for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.3401+0.528 * 1.5861+0.404 * 1.1189+0.892 * 2.8721+0.115 * 0.5548
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.2628+4.679 * -1.646889-0.327 * 0.8054
=-8.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep22) TTM:Last Year (Sep21) TTM:
Total Receivables was $0.30 Mil.
Revenue was 0.109 + 0.09 + 0.022 + 0.026 = $0.25 Mil.
Gross Profit was 0.068 + 0.03 + 0.008 + -0.039 = $0.07 Mil.
Total Current Assets was $0.46 Mil.
Total Assets was $0.69 Mil.
Property, Plant and Equipment(Net PPE) was $0.13 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.09 Mil.
Selling, General, & Admin. Expense(SGA) was $1.42 Mil.
Total Current Liabilities was $16.15 Mil.
Long-Term Debt & Capital Lease Obligation was $0.15 Mil.
Net Income was 0.577 + -0.646 + 5.013 + 2.169 = $7.11 Mil.
Non Operating Income was 1.035 + -0.127 + 5.515 + 2.77 = $9.19 Mil.
Cash Flow from Operations was -0.165 + -0.285 + -0.258 + -0.234 = $-0.94 Mil.
Total Receivables was $0.30 Mil.
Revenue was 0.019 + 0.03 + 0.022 + 0.015 = $0.09 Mil.
Gross Profit was 0.01 + 0.021 + 0.016 + -0.01 = $0.04 Mil.
Total Current Assets was $0.57 Mil.
Total Assets was $0.84 Mil.
Property, Plant and Equipment(Net PPE) was $0.16 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.05 Mil.
Selling, General, & Admin. Expense(SGA) was $1.88 Mil.
Total Current Liabilities was $23.78 Mil.
Long-Term Debt & Capital Lease Obligation was $0.68 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.295 / 0.247) / (0.302 / 0.086)
=1.194332 / 3.511628
=0.3401

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.037 / 0.086) / (0.067 / 0.247)
=0.430233 / 0.271255
=1.5861

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (0.462 + 0.129) / 0.691) / (1 - (0.572 + 0.155) / 0.835)
=0.144718 / 0.129341
=1.1189

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.247 / 0.086
=2.8721

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.045 / (0.045 + 0.155)) / (0.088 / (0.088 + 0.129))
=0.225 / 0.40553
=0.5548

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1.418 / 0.247) / (1.879 / 0.086)
=5.740891 / 21.848837
=0.2628

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.152 + 16.148) / 0.691) / ((0.68 + 23.775) / 0.835)
=23.589001 / 29.287425
=0.8054

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(7.113 - 9.193 - -0.942) / 0.691
=-1.646889

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Nutra Pharma has a M-score of -8.63 suggests that the company is unlikely to be a manipulator.


Nutra Pharma Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Nutra Pharma's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Nutra Pharma (Nutra Pharma) Business Description

Traded in Other Exchanges
N/A
Address
1537 NW 65th Avenue, Plantation, FL, USA, 33313
Nutra Pharma Corp operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. It also develops proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Some of its drug names are Cobroxin, Nyloxin, RPI-78M, RPI-MN and Pet Pain-Away.
Executives
Rik J Deitsch officer: Chief Executive Officer 4001 NW 73 WAY, CORAL SPRINGS FL 33065
Dan Oran director 8411 W OAKLAND PARK BLVD, #201, SUNRISE FL 33351
Bruno Sartori other: Former CFO 275 COMMERCIAL BLVD, STE 260, FT LAUDERDALE FL 33308
Harold Henry Rumph director, officer: President - ReceptoPharm 1537 N.W. 65TH AVENUE, PLANTATION FL 33313
David Michael Isserman officer: Chief Marketing Officer 2776 UNIVERSITY DRIVE, CORAL SPRINGS FL 33065
Garry Pottruck director 10768 NW 18TH CT, CORAL SPRINGS FL 33071
Paul F Reid director 9610 NW 24 CT, SUNRISE FL 33322
Michael Doherty director, officer: Executive Chairman
Tanvir A Khandaker director 387 PARK AVENUE SOUTH THIRD FLOOR, NEW YORK NY 10016
Stewart Alan Lonky director 1158 CHAUTAUQUA BLVD., PACIFIC PALISADES CA 90272
Stanley Jack Cherelstein director 2401 SW MANOR HILL DRIVE, PALM CITY FL 34990
Michael Flax director, officer: Chief Financial Officer 2499 BANYAN RD, BOCA RATON FL 33432
Mcclelland David C Sr director P.O. BOX 263, FINDLEY LAKE NY 14736
Mitchell S Felder director PO BOX 1332, HERMITAGE PA 16148
Khalsa Soram Singh Md director 436 N BEDFORD DR, BEVERLY HILLS CA 90210

Nutra Pharma (Nutra Pharma) Headlines

From GuruFocus

Nutra Pharma Partners with NxGen Brands for Nyloxin® Distribution

By Marketwired Marketwired 04-19-2018